Semaglutide (GLP-1 Analogue) 6mg PeptideSciences

Buy Semaglutide (GLP-1 Analogue) 6 mg online 

Semaglutide is a derivative of GLP-1, a peptide that has been shown to be a regulator of blood sugar levels and a stimulator of insulin secretion. Several studies have also shown that semaglutide may have positive effects on heart, liver, and lung function and may help slow or halt the progression of Alzheimer's disease. Semaglutide may also reduce appetite by staying in the stomach longer. It may also reduce muscle activity in the bowel. Glucagon-like peptide-1 (GLP-1) analogs can control the effects of glucose levels on the secretion of insulin and glucagon. Buy Semaglutide 3mg online without a doctor's prescription for your personal use in our online pharmacy.

Semaglutide and GLP-1 at a glance

GLP-1 is the abbreviation for glucagon-like peptide-1 and is a small peptide hormone consisting of only thirty to thirty-one amino acids. Regulating blood glucose levels by increasing insulin secretion is its main physiological role. It is also directly involved in neurotrophic functions in the brain and CNS, protecting beta-cell insulin stores and stimulating the growth of insulin genes. In the digestive tract, GLP-1 has been shown to reduce appetite by slowing down the emptying of the stomach and slowing down the contractions of the bowel. In addition, experimental work has identified possible effects of GLP-1 in the heart, fat, muscle, bone, liver, lung, kidney and other parts of the body. 

The main area of research into GLP-1 has been diabetes mellitus/obesity treatment and prevention. The effects of the peptide on the cardiovascular system have been a secondary focus. Finally, the ability of GLP-1 to reduce the risk of neurodegenerative diseases is a more recent and therefore more speculative area of research. Although this last area is the most recent in the literature, it is also a rapidly developing area of GLP-1 research, now that the peptide has been shown to delay or even stop the formation of the amyloid beta plaques associated with Alzheimer's disease.

Semaglutide formulation 

Sequence: HXEGTFTSDVSSYLEGQAAK-OH.steric diacid-EFIAWLVRGRG 
Molecular Formula: C187H291N45O59 
Molecular Weight: 4113.64 g/mol 
PubChem CID: 56843331 
CAS Number: 910463-68-2 
Synonyms: Semaglutide, Ozempic, Rybelsus, NN9535

Studies with semaglutide and GLP-1 - The effect of GLP-1 as an incretin hormone 

One of the last effects of GLP-1, says Holst, is the "incretin effect", a group of metabolic hormones released by the small intestine that reduce blood sugar levels. GLP-1 is one of two hormones, the other being GIP, that have been shown to increase the incretin effect in rodents. Researchers have found that GLP-1 is much more effective than GIP, especially when blood glucose levels are high, although GIP circulates at about 10 times the concentration of GLP-1.

GLP-1 has been shown to directly stimulate the release of insulin from the pancreas through a specific GLP-1 receptor located on the outside of the pancreatic beta cells. GLP-1 in combination with sulfonylureas stimulates insulin secretion in type 2 diabetics to such an extent that 40% experience symptomatic hypoglycemia. Naturally, increased insulin secretion is associated with a number of nutritional effects, including higher rates of protein synthesis, slower protein breakdown and increased skeletal muscle amino acid uptake.

Protection of GLP-1 and beta cells 

Animal studies have also shown that GLP-1 can promote the development of pancreatic beta cells. New research suggests that GLP-1 can induce pancreatic ductal epithelial progenitor cells to develop into beta cells. GLP-1 has also been shown to block the apoptosis of beta cells. Taken together, these effects shift the balance between proliferation and apoptosis of beta cells in favour of proliferation, so that the peptide could be used to treat diabetes and to protect the pancreas from damage that has a negative effect on beta cells. 

One of the most compelling studies has shown that GLP-1 has an inhibitory effect on beta cell death with increased levels of inflammatory cytokines. In addition, investigations in genetic mouse models of type 1 diabetes have shown that GLP-1 also has a direct effect on preventing the destruction of pancreatic islet cells, which may play a potential role in preventing the development of type 1 diabetes.

Some words regarding GLP-1 and appetite control 

Animal studies have shown that the administration of GLP-1 and the GLP-1 receptor to the brains of mice can significantly slow down the intake of calories and reduce the obsession with food. It now appears that GLP-1 might somehow help to increase satiety, or the feeling of fullness, and thus reduce hunger. 

GLP-1 receptor agonist treatment leads to a sustained but progressive loss of body weight. There was also a reduction in haemoglobin A1C, a parameter of disease severity and a marker of glycaemic control achieved with treatment.

Possible cardiovascular effects from GLP-1  

In humans, GLP-1 is expressed throughout the heart and promotes specific aspects of cardiac function by increasing overall heart rate and LV pressure. The latter may seem small. However, increased LV end-diastolic pressure is a sign of LV hypertrophy, heart enlargement and end-stage heart failure. More recent research has suggested that GLP-1 may have a role in the reduction of overall heart attack damage. 

The peptide seems to increase the rate of glucose uptake in the myocardium, helping the damaged, ischaemic myocardium to obtain the nutrients needed to keep working instead of signalling cell death. 

The increase in the rate of glucose uptake in these cells is not thought to be mediated by insulin, but is a result of the action of the hormone GLP-1. High-dose intravenous GLP-1 improves LV function and decreases SVR in dogs. The latter may help to reduce blood pressure, resulting in reduced cardiac workload. This may help to minimise the degree of LV remodelling, the progression of arterial wall hypertrophy and the development of heart failure as a complication of high blood pressure.

Dr Holst noted that "GLP-1 administration after myocardial injury consistently improved myocardial performance not only in experimental animal models but also in patients".

Here is some information about GLP-1 and the brain 

For example, there is some evidence that GLP-1 may improve learning and act as a protective shield for neurons in neurodegenerative diseases such as Alzheimer's. In addition, a study has shown that GLP-1 has an effect on learning and memory processing in mice and reverses learning deficits in mouse models with specific gene deletions. In rats, overexpression of the GLP-1 receptor in certain regions of the brain improves both learning and memory compared to normal rats. 

GLP-1 has also been shown to protect against excitotoxic neuronal damage by rescuing all of the rat models of neurodegeneration from the apoptotic death induced by glutamate. This peptide can also induce neurite regeneration in cultured cells. It is not hard to imagine that some neurodegenerative diseases could be halted or even reversed by further studies with GLP-1. In particular, GLP-1 and its receptor agonist, exendin-4, have been reported to suppress brain amyloid beta deposition and beta-amyloid precursor protein in neurons in mouse models. 

The main protein in the plaques seen in Alzheimer's disease is amyloid beta, which, although not known to cause the disease, is proportional to the severity of the disease. However, this trial is an example of how researchers may try to interrupt the progression from mild cognitive impairment to Alzheimer's disease, regardless of whether stopping the build-up of amyloid-beta can protect against the effects of Alzheimer's disease. 

The side effects are mild to moderate and the bioavailability is high in the mice, but excellent under the skin. Mouse dose per kg bw does not match human dose. At Peptide Sciences, we supply GLP-1 specifically for research purposes, not for medicinal or food use. GLP-1 should therefore only be purchased by licensed researchers.